61 results about "Tuberculosis prophylaxis" patented technology

The present invention relates to fusion proteins of Mycobacterium tuberclosis antigens. In particular, it relates to two fusion proteins, each of which contains three individual M. tuberculosis antigens, and a fusion protein of two M. tuberculosis antigens, their coding sequences, and methods for their use in the treatment and prevention of tuberculosis.

The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.

The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.

The invention discloses an application of single nucleotide polymorphism rs3888188 to detection of tuberculosis susceptibility. The SNP (Single Nucleotide Polymorphism) is the rs3888188 and is positioned in a human IFITM3 (interferon induced transmembrane protein) gene core promoter region (namely the upstream 103bp of a transcription initiation site/the upstream 204bp of a translation initiation site ATG), the rs3888188G is a risk factor of tuberculosis susceptibility, and the polymorphism of the rs3888188 is highly related with tuberculosis. When the genotype of the site is GG, the tuberculosis susceptibility or tuberculosis causing risk of an individual to be detected is increased. The application is of significant meaning and value in the aspects of diagnosing and treating the tuberculosis to reasonably prevent the tuberculosis.

Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.

The invention relates to the construction of a human GM-CSF gene and Mycobacterium tuberculosis ESAT6 gene chimerically expressed GMCSF-ESAT6 protein recombinant Bacillus Calmette Guerin (BCG) vaccine and immunogenicity research thereof, namely the sequence of the human GM-CFS gene and the sequence of the Mycobacterium tuberculosis ESAT6 gene are inserted into the sequence of the same escherichiacoli-Mycobacterium tuberculosis shuttle plasmid pMV361 by gene engineering technology so as to construct a recombinant shuttle plasmid rpMV361GMCSF-ESAT6; and a vector is introduced into a BCG vaccine by an electroporation method so as to construct a recombinant BCG vaccine rBCG:GMCSF-ESAT6. The recombinant BCG vaccine can express the human GM-CSF and Mycobacterium tuberculosis ESAT6 gene chimeric protein GMCSF-ESAT6 stably, and has an immunogenicity superior to that of the conventional BCG vaccine. The invention provides a process for preparing the recombinant BCG vaccine, researches the immunity thereof, and belongs to the field of gene engineering and the field of tuberculosis vaccine. The novel recombinant vaccine prevents the generation and the propagration of tuberculosis more effectively.

Disclosed are yeast-based immunotherapeutic compositions and fusion proteins for the treatment and/or prevention of TB infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions and fusion proteins for the prophylactic and/or therapeutic treatment of TB and/or symptoms thereof.

The invention is within the field of immunology and microbiology, more specifically the field of mycobacteriology and is related to immunotherapy and prophylaxis of tuberculosis and related diseases. The composition useful for these purposes is disclosed, including the methods of using said composition.

Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol hydrolase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.

The present invention relates to 4-pyrimidinylamino-benzenesulfonamide derivatives of general formula (I) and pharmaceutically acceptable salts, solvates, hydrates, regioisomeric and polymorphic forms thereof, processes for manufacturing of them, the use of them, as well as pharmaceutical compositions containing at least one of them as pharmaceutically active agent(s) together with pharmaceutically acceptable carrier, excipient and/or diluents, especially for the inhibition of polo-like kinases (PLKs) and the treatment of cancer. Said 4-pyrimidinylamino-benzenesulfonamide compounds have been also identified as new drug candidates for the prevention and/or treatment of infectious diseases like bacterial diseases e.g. tuberculosis, including the currently multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB) as well as for preventing tuberculosis.

An inactivated mycobacteria for oral use in the prevention of tuberculosis, which are administered using a multi-dose regimen and with a reduced time interval between doses, such as to induce a tolerance-building to infection by the tubercle bacillus. The inactivated bacteria can be used with the aforementioned regimen to control the progression of the infection from a latent state to active tuberculosis.

The possibility of using betulin and birch bark containing said betulin for treating and preventing tuberculosis is disclosed.

The invention belongs to the field of biomedicines, and relates to an application of vitamin C (ascorbic acid), as a single component, in preparation of medicines for treating and preventing tuberculosis. Through cytobiology and pharmacology experiments with combination of animal experiments, anti-tuberculosis pharmaceutical concentration of the vitamin C is determined; and on the basis of regulatory mechanism on oxidative stress status of mycobacterium tuberculosis after infection by macrophages, interference test is carried out, wherein a result proves that high-dose vitamin C can kill the mycobacterium tuberculosis, so that inhibition effect is achieved through NAC and catalase; the vitamin C treats the macrophages to generate H2O2, wherein functional effect is achieved with the signalchannel being same as H2O2; large-dose vitamin C kills mycobacteria, wherein inhibition function is achieved through a glutathione precursor NAC and CAT; high-dose vitamin C can infect the TNF-alpha signal pathway induced by RAW 264.7 cells via mediation of Bacillus Calmette-Guerin vaccine and H37Rv, thus achieving sterilization effect and influence on body immunity. The invention provides effective treatment strategy for clinical therapy and drug resistance of tuberculosis and tuberculosis in incubation period.

The present invention relates to a chimeric DNA vaccine for preventing tuberculosis and immunotherapy, comprising a full-length open reading frame of the nucleotide sequence shown in SEQ ID NO.1, or a conservative variant thereof, in SEQ ID NO.1 It comprises mycobacterium hsp70 gene and human B7-1 gene, and a linker sequence is designed between the two genes to connect them. The vaccine of the invention can be used for tuberculosis caused by Mycobacterium tuberculosis; or express the corresponding protein in eukaryotic cells in vitro for preventing and treating tuberculosis. It can also be used as an immune enhancer for corresponding viral diseases and tumor immunotherapy.

The invention provides application of bovine beta defensin 5 as a mucosal immunologic adjuvant in prevention of tuberculosis. A C57BL/6 mouse is immunized by expressing and purifying recombinant protein bovine beta defensin 5, combining polyinosinic-polycytidylic acid (PolyI: C) and a mycobacterium tuberculosis protein subunit vaccine AH in a nasal drop mode, and the effect of promoting the immune effect of the protein subunit vaccine AH is proved. Compared with polyinosinic-polycytidylic acid and AH immunization, the bovine beta defensin 5 can promote antigen AH specific cellular immunization and humoral immunization levels and promote the protective effect of subunit vaccine AH on resisting bovine mycobacterium infection.

The invention relates to construction of a chimeric protein Dodecin-ESAT6 candidate vaccine of an ESAT6 gene and an RV1498a gene of mycobacterium tuberculosis, and immunogenicity research of the chimeric protein Dodecin-ESAT6 candidate vaccine, i.e., through a genetic engineering technique, sequences of the ESAT6 gene and the RV1498a gene of the mycobacterium tuberculosis are inserted into sequences of the same escherichia coli plasmid pET28a, and a recombinant plasmid rpET28a:RV1498a-ESAT6 is constructed; and by a heat shock transforming method, carriers are guided into escherichia coli, andfusion protein Dodecin-ESAT6 is expressed. The expressed fusion protein Dodecin-ESAT6 is constructed, and the immunogenicity is better than that of ESAT6. The invention provides a preparation processof the fusion protein Dodecin-ESAT6, researches the immunogenicity of the fusion protein Dodecin-ESAT6, and belongs to the field of genetic engineering and the field of tuberculosis vaccines. Occurrence and propagation of tuberculosis can be effectively prevented.

The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.

The invention provides liposome formulations comprising fragments from a Mycobacterium tuberculosis-complex strain, it also provides a Mycobacterium tuberculosis-complex strain, fragments of which may be incorporated into selected embodiments of the liposome formulation. The invention further provides suspensions and pharmaceutical compositions comprising the liposome formulations. Furthermore, it discloses the use of the liposome formulations for use in a method of treatment of the human or animal body by therapy, in particular for use in a method of treating or preventing tuberculosis, such as in preventing latent tuberculosis or in tuberculosis prophylaxis, optionally in combination therapy. The formulation of this invention contains sucrose and/or has a lower average particle size than conventional liposome-based agents of tuberculosis therapy, resulting in higher bioavailability and efficiency.

The invention belongs to the biomedical field, in particular to the use of Bacteroides fragilis in the preparation of drugs for the treatment and prevention of tuberculosis. The invention also provides the application of Bacteroides fragilis in the preparation of pharmaceutical compositions, foods, health products and food additives for treating and/or preventing tuberculosis. The Bacteroides fragilis provided by the invention can effectively treat and/or prevent tuberculosis and enhance the immune protection effect of tuberculosis bacillus Calmette-Guerin vaccine (BCG), and has wide application prospect.

The invention discloses vaccine and a combination medicine for preventing tuberculosis, a method for preparing the vaccine and application, and belongs to the field of medicines for treating tuberculosis latent infection. By the aid of the vaccine with mycobacterium microbial compound adjuvants for preventing the tuberculosis, the problems of ineffectiveness or poor effects of existing subunit vaccine for treating tubercle bacillus latent infected population, diversified adjuvants, hypersensitivity and Koch reaction risks can be pertinently solved. The vaccine with mycobacterium microbial compound adjuvants for preventing the tuberculosis comprises Ag85b proteins, ESAT6-CFP10 proteins and mycobacterium vaccae thallus extract. The vaccine, the combination medicine, the method and the application have the advantages that the vaccine with the mycobacterium microbial compound adjuvants for preventing the tuberculosis is used for treating latent tuberculosis infection, and obvious effects can be realized; the vaccine only comprises a single type of adjuvants, and accordingly hypersensitivity and Koch reaction risks can be prevented.